Wyeth, Elan Halt Alzheimer Drug Trial
ACC-001 is a vaccine designed to prime the body's immune system to create antibodies against beta amyloid, the toxic protein that forms plaques in the brain believed to play a key role in Alzheimer disease.
Wyeth and Elan are developing ACC-001 as a second-generation version of an older Alzheimer vaccine, AN1792. The latter vaccine's development was stopped in 2001 after some patients were hospitalized due to swelling in the brain.
According to Elan spokesman Jonathan Birt, one patient dosed with ACC-001 in a phase II trial was hospitalized with what the patient's physician described as a "skin lesion, possibly vasculitis." The patient was treated successfully and has since been discharged from the hospital.Vasculitis is an inflammation of blood vessels that can be caused by an immune, or allergic, reaction. The severity of vasculitis can vary widely, but Birt had no more information about the ACC-001 patient. A later biopsy, however, did not confirm vasculitis, according to a Wyeth spokesperson. Elan and Wyeth have informed regulators both in the U.S. and Europe about the hospitalization, which led to the suspension of the ACC-001 clinical trial. The study has not been permanently halted, Birt says. A notice of the ACC-001 study suspension was posted on the ClinicalTrials.gov Web site. The negative safety signal detected with ACC-001 has not affected the ongoing clinical trials of bapineuzumab, the other major Alzheimer drug being developed by Elan and Wyeth, Birt says. Thursday's news comes one day after Elan shares rose sharply after the company and partner Biogen Idec (BIIB) reported a stronger-than-expected increase in the number of patients treated with their multiple sclerosis drug Tysabri. Elan shares were down 4.1% at $23.31 in recent trading, while Wyeth shares were losing 1.5% to $43.57.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV